Chitin, chitosan, and glycated chitosan regulate immune responses: The novel adjuvants for cancer vaccine

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Li, Xiaosong ^a   Min, Min ^b   Du, Nan ^a   Gu, Ying ^a   Hode, Tomas ^c   Naylor, Mark ^d   Chen, Dianjun ^a   Nordquist, Robert E ^c   Chen, Wei R ^e  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c ImmunoPhotonics Inc   (United States)

^d Dermatology Associates of San Antonio   (United States)

^e UNIVERSITY OF CENTRAL OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM; ALUMINUM HYDROXIDE; ANTIGEN; CALRETICULIN; CANCER VACCINE; CHITIN; CHITOSAN; CHITOSAN DERIVATIVE; DOCETAXEL; DOXORUBICIN; GAMMA INTERFERON; HEAT SHOCK PROTEIN; IMMUNOGLOBULIN ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; NANOPARTICLE; NORCANTHARIDIN; OVALBUMIN; PACLITAXEL; PHOSPHORYL LIPID A; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VIROSOME; GLYCATED CHITOSAN;

ANTINEOPLASTIC ACTIVITY; BIODEGRADABILITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHEMICAL STRUCTURE; CONTROLLED DRUG RELEASE; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; ESCHERICHIA COLI INFECTION; GLYCATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; SPLEEN CELL; T LYMPHOCYTE; WOUND HEALING; ANIMAL; IMMUNOLOGY; NEOPLASM;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CHITIN; CHITOSAN; HUMANS; NEOPLASMS;

MLCS; MLOWN;

EID: 84875470203     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/387023     Document Type: Review

References (98)

1. Mellman I., Coukos G., Dranoff G., Cancer immunotherapy comes of age. Nature 2011 480 7378 480 489
2. Vanneman M., Dranoff G., Combining immunotherapy and targeted therapies in cancer treatment. Nature Reviews Cancer 2012 12 4 237 251
3. Finn O. J., Molecular origins of cancer: cancer immunology. The New England Journal of Medicine 2008 358 25 2704 2715 2-s2.0-45549092607 10.1056/NEJMra072739 (Pubitemid 351860863)
4. Zhou G., Levitsky H., Towards curative cancer immunotherapy: overcoming posttherapy tumor escape. Clinical and Developmental Immunology 2012 2012 12 124187 10.1155/2012/124187
5. Zindl C. L., Chaplin D. D., Immunology: tumor immune evasion. Science 2010 328 5979 697 698 2-s2.0-77952232433 10.1126/science.1190310
6. Pardoll D. M., The blockade of immune checkpoints in cancer immunotherapy. NatureReviews Cancer 2012 12 4 252 264
7. Batista-Duharte A., Lindblad E. B., Oviedo-Orta E., Progress in understanding adjuvant immunotoxicity mechanisms. Toxicology Letters 2011 203 2 97 105 2-s2.0-79955473746 10.1016/j.toxlet.2011.03.001
8. Montomoli E., Piccirella S., Khadang B., Current adjuvants and new perspectives invaccine formulation. Expert Review of Vaccines 2011 10 7 1053 1061
9. Schijns V. E. J. C., Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants. Vaccine 2003 21 9-10 829 831 2-s2.0-0037435926 10.1016/S0264-410X(02)00527-3 (Pubitemid 36126414)
10. Seya T., Akazawa T., Uehori J., Matsumoto M., Azuma I., Toyoshima K., Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Research 2003 23 6 A 4369 4376 2-s2.0-0344009684 (Pubitemid 37474889)
11. Allison A. C., Squalene and squalane emulsions as adjuvants. Methods 1999 19 1 87 93 2-s2.0-0032724999 10.1006/meth.1999.0832 (Pubitemid 29497757)
12. Felnerova D., Viret J. F., Glück R., Moser C., Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Current Opinion in Biotechnology 2004 15 6 518 529 2-s2.0-9244234954 10.1016/j.copbio.2004.10.005 (Pubitemid 39551004)
13. Schwaninger R., Waelti E., Zajac P., Wetterwald A., Mueller D., Gimmi C. D., Virosomes as new carrier system for cancer vaccines. Cancer Immunology, Immunotherapy 2004 53 11 1005 1017 2-s2.0-5644241854 10.1007/s00262-004-0545-5 (Pubitemid 39371745)
14. Gnjatic S., Sawhney N. B., Bhardwaj N., Toll-like receptor agonists are they good adjuvants? Cancer Journal 2010 16 4 382 391 2-s2.0-77957982756 10.1097/PPO.0b013e3181eaca65
15. Adams S., Toll-like receptor agonists in cancer therapy. Immunotherapy 2009 1 6 949 964
16. Plohmann B., Bader G., Hiller K., Franz G., Immunomodulatory and antitumor effects of triterpenoid saponins. Pharmazie 1997 52 12 953 957 2-s2.0-0031283477 (Pubitemid 28010885)
17. Glenny A. T., Pope C. G., Waddington H., Immunological notes XVII to XXIV. The Journal of Pathology and Bacteriology 1926 29 31 40
18. Vogel F. R., Powell M. F., A compendium of vaccine adjuvants and excipients. Pharmaceutical Biotechnology 1995 6 141 228 2-s2.0-0029200883
19. Yang M., Yan Y., Fang M., MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1(+) tumor immunity in mice. International Immunopharmacology 2012 13 4 408 416
20. Cluff C. W., Monophosphoryl lipid a (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Advances in Experimental Medicine and Biology 2009 667 111 123 2-s2.0-77952540334 10.1007/978-1-4419-1603-7-10
21. Gupta R. K., Siber G. R., Adjuvants for human vaccines. Current status, problems and future prospects. Vaccine 1995 13 14 1263 1276 2-s2.0-0028884598 10.1016/0264-410X(95)00011-O
22. Hoft D. F., Brusic V., Sakala I. G., Optimizing vaccine development. Cellular Microbiology 2011 13 7 934 942
23. Cebon J., Cancer vaccines: where are we going? Asia-Pacific Journal of Clinical Oncology 2010 6 supplement 1 S9 S15 2-s2.0-77950802427 10.1111/j.1743-7563.2010.01270.x
24. Schlom J., Therapeutic cancer vaccines: current status and moving forward. Journal of the National Cancer Institute 2012 104 8 599 613
25. Krajewska B., Membrane-based processes performed with use of chitin/chitosan materials. Separation and Purification Technology 2005 41 3 305 312 2-s2.0-13844307671 10.1016/j.seppur.2004.03.019 (Pubitemid 40259111)
26. Muzzarelli R. A. A., Human enzymatic activities related to the therapeutic administration of chitin derivatives. Cellular and Molecular Life Sciences 1997 53 2 131 140 2-s2.0-0030748702 10.1007/PL00000584 (Pubitemid 27365884)
27. Pillai C. K. S., Paul W., Sharma C. P., Chitin and chitosan polymers: chemistry, solubility and fiber formation. Progress in Polymer Science 2009 34 7 641 678
28. Zhao Y., Park R. D., Muzzarelli R. A. A., Chitin deacetylases: properties and applications. Marine Drugs 2010 8 1 24 46 2-s2.0-76149085543 10.3390/md8010024
29. Synowiecki J., Al-Khateeb N. A., Production, properties, and some new applications of chitin and its derivatives. Critical Reviews in Food Science and Nutrition 2003 43 2 145 171 2-s2.0-0038495578 10.1080/10408690390826473 (Pubitemid 38552306)
30. Kato Y., Onishi H., Machida Y., Application of chitin and chitosan derivatives in the pharmaceutical field. Current Pharmaceutical Biotechnology 2003 4 5 303 309 2-s2.0-0141504461 10.2174/1389201033489748 (Pubitemid 37220862)
31. Gades M. D., Stern J. S., Chitosan supplementation and fat absorption in men and women. Journal of the American Dietetic Association 2005 105 1 72 77 2-s2.0-11344284485 10.1016/j.jada.2004.10.004 (Pubitemid 40075495)
32. Kaats G. R., Michalek J. E., Preuss H. G., Evaluating efficacy of a chitosan product using a double-blinded, placebo-controlled protocol. Journal of the American College of Nutrition 2006 25 5 389 394 2-s2.0-33749474867 (Pubitemid 44522575)
33. Jarmila V., Vavríková E., Chitosan derivatives with antimicrobial, antitumour and antioxidant activities-a review. Current Pharmaceutical Design 2011 17 32 3596 3607
34. Mahapatro A., Singh D. K., Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. Journal of Nanobiotechnology 2011 9 55
35. Patel M. P., Patel R. R., Patel J. K., Chitosan mediated targeted drug delivery system: a review. Journal of Pharmacy and Pharmaceutical Sciences 2010 13 4 536 557 2-s2.0-78650342641
36. Fonte P., Andrade J. C., Seabra V., Chitosan-based nanoparticles as delivery systems of therapeutic proteins. Methods in Molecular Biology 2012 899 471 487
37. Dai T., Tanaka M., Huang Y. Y., Hamblin M. R., Chitosan preparations for wounds and burns: antimicrobial and wound-healing effects. Expert Review of Anti-Infective Therapy 2011 9 7 857 879 2-s2.0-79961182508 10.1586/eri.11.59
38. Takei T., Nakahara H., Ijima H., Synthesis of a chitosan derivative soluble at neutral pH and gellable by freeze-thawing, and its application in wound care. Acta Biomaterialia 2012 8 2 686 693
39. Suzuki K., Okawa Y., Hashimoto K., Protecting effect of chitin and chitosan on experimentally induced murine candidiasis. Microbiology and Immunology 1984 28 8 903 912 2-s2.0-0021221857 (Pubitemid 14030257)
40. Nishimura K., Nishimura S., Nishi N., Immunological activity of chitin and its derivatives. Vaccine 1984 2 1 93 99 2-s2.0-0021679779 (Pubitemid 15167639)
41. Nishimura K., Ishihara C., Ukei S., Stimulation of cytokine production in mice using deacetylated chitin. Vaccine 1986 4 3 151 156 2-s2.0-0022965178 (Pubitemid 17170305)
42. Nishimura K., Nishimura S. I., Nishi N., Adjuvant activity of chitin derivatives in mice and guinea-pigs. Vaccine 1985 3 5 379 384 2-s2.0-0022365282 (Pubitemid 16201992)
43. van der Lubben I. M., Verhoef J. C., Borchard G., Junginger H. E., Chitosan for mucosal vaccination. Advanced Drug Delivery Reviews 2001 52 2 139 144 2-s2.0-0035813652 10.1016/S0169-409X(01)00197-1 (Pubitemid 33079169)
44. Read R. C., Naylor S. C., Potter C. W., Effective nasal influenza vaccine delivery using chitosan. Vaccine 2005 23 35 4367 4374 (Pubitemid 40991223)
45. McNeela E. A., Jabbal-Gill I., Illum L., Pizza M., Rappuoli R., Podda A., Lewis D. J. M., Mills K. H. G., Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 2004 22 8 909 914 2-s2.0-1242270653 10.1016/j.vaccine.2003.09.012 (Pubitemid 38221084)
46. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A. N., Davis S. S., Chitosan as a novel nasal delivery system for vaccines. Advanced Drug Delivery Reviews 2001 51 1-3 81 96 2-s2.0-0035940314 10.1016/S0169-409X(01)00171-5 (Pubitemid 32763074)
47. Heffernan M. J., Zaharoff D. A., Fallon J. K., Schlom J., Greiner J. W., In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines. Biomaterials 2011 32 3 926 932 2-s2.0-78549270045 10.1016/j.biomaterials.2010. 09.058
48. Azab A. K., Doviner V., Orkin B., Kleinstern J., Srebnik M., Nissan A., Rubinstein A., Biocompatibility evaluation of crosslinked chitosan hydrogels after subcutaneous and intraperitoneal implantation in the rat. Journal of Biomedical Materials Research A 2007 83 2 414 422 2-s2.0-35048867035 10.1002/jbm.a.31256 (Pubitemid 47557391)
49. Yao J., Zhou J. P., Ping Q. N., Lu Y., Chen L., Distribution of nobiletin chitosan-based microemulsions in brain following i.v. injection in mice. International Journal of Pharmaceutics 2008 352 1-2 256 262 2-s2.0-39449135377 10.1016/j.ijpharm.2007.10.010 (Pubitemid 351273917)
50. Kwak C., Sung K. H., Seung K. S., Jei M. R., Moon S. P., Sang E. L., Effective local control of prostate cancer by intratumoral injection of 166Ho-chitosan complex (DW-166HC) in rats. European Journal of Nuclear Medicine and Molecular Imaging 2005 32 12 1400 1405 2-s2.0-28544449828 10.1007/s00259-005-1892-y (Pubitemid 41746843)
51. Shibata Y., Foster L. A., Metzger W. J., Alveolar macrophage priming by intravenous administration of chitin particles, polymers of N-acetyl-D- glucosamine, in mice. Infection and Immunity 1997 65 5 1734 1741 (Pubitemid 27193594)
52. Shibata Y., James Metzger W., Myrvik Q. N., Chitin particle-induced cell-mediated immunity is inhibited by soluble mannan: mannose receptor-mediated phagocytosis initiates IL-12 production. Journal of Immunology 1997 159 5 2462 2467 2-s2.0-0031225516 (Pubitemid 127681041)
53. Tokura S., Tamura H., Azuma I., Immunological aspects of chitin and chitin derivatives administered to animals. EXS 1999 87 279 292 2-s2.0-0033287335
54. Lee C. G., Da Silva C. A., Lee J. Y., Hartl D., Elias J. A., Chitin regulation of immune responses: an old molecule with new roles. Current Opinion in Immunology 2008 20 6 684 689 2-s2.0-56349119852 10.1016/j.coi.2008.10.002
55. Lee C. G., Chitin, chitinases and chitinase-like proteins in allergic inflammation and tissue remodeling. Yonsei Medical Journal 2009 50 1 22 30 2-s2.0-62749191275 10.3349/ymj.2009.50.1.22
56. Da Silva C. A., Pochard P., Lee C. G., Elias J. A., Chitin particles are multifaceted immune adjuvants. American Journal of Respiratory and Critical Care Medicine 2010 182 12 1482 1491 2-s2.0-78650189266 10.1164/rccm.200912-1877OC
57. Marcinkiewicz J., Polewska A., Knapczyk J., Immunoadjuvant properties of chitosan. Archivum Immunologiae Et Therapiae Experimentalis 1991 39 1-2 127 132
58. Seferian P. G., Martinez M. L., Immune stimulating activity of two new chitosan containing adjuvant formulations. Vaccine 2000 19 6 661 668 2-s2.0-0034623660 10.1016/S0264-410X(00)00248-6
59. Zaharoff D. A., Rogers C. J., Hance K. W., Schlom J., Greiner J. W., Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 2007 25 11 2085 2094 2-s2.0-33846857760 10.1016/j.vaccine.2006.11.034 (Pubitemid 46227669)
60. Zaharoff D. A., Rogers C. J., Hance K. W., Schlom J., Greiner J. W., Chitosan solution enhances the immunoadjuvant properties of GM-CSF. Vaccine 2007 25 52 8673 8686 2-s2.0-36549067721 10.1016/j.vaccine.2007.10.037 (Pubitemid 350192060)
61. Zaharoff D. A., Hance K. W., Rogers C. J., Schlom J., Greiner J. W., Intratumoral immunotherapy of established solid tumors with chitosan/il-12. Journal of Immunotherapy 2010 33 7 697 705 2-s2.0-77955175116 10.1097/CJI.0b013e3181eb826d
62. Mourya V. K., Inamdar N. N., Trimethyl chitosan and its applications in drug delivery. Journal of Materials Science. Materials in Medicine 2009 20 5 1057 1079
63. Lee D., Quan Z. S., Lu C., Preparation and physical properties of chitosan benzoic acid derivatives using a phosphoryl mixed anhydride system. Molecules 2012 17 2 2231 2239
64. Bajaj G., Van Alstine W. G., Yeo Y., Zwitterionic chitosan derivative, a new biocompatible pharmaceutical excipient, prevents endotoxin-mediated cytokine release. PLoS ONE 2012 7 1 e30899
65. Li X., Wu P., Gao G. F., Carbohydrate-functionalized chitosan fiber for influenza virus capture. Biomacromolecules 2011 12 11 3962 3969
66. Chung Y. C., Yeh J. Y., Tsai C. F., Antibacterial characteristics and activity of water-soluble chitosan derivatives prepared by the Maillard reaction. Molecules 2011 16 10 8504 8514
67. Sugano M., Watanabe S., Kishi A., Hypocholesterolemic action of chitosans with different viscosity in rats. Lipids 1988 23 3 187 191 (Pubitemid 18080601)
68. Song S., Zhou F., Nordquist R. E., Carubelli R., Liu H., Chen W. R., Glycated chitosan as a new non-toxic immunological stimulant Glycated chitosan immunological stimulant. Immunopharmacology and Immunotoxicology 2009 31 2 202 208 2-s2.0-70350633523 10.1080/08923970802629593
69. Xu F., Liu H., Wu X., Measurement of x-ray attenuation coefficients of aqueous solutions of indocyanine green and glycated chitosan. Medical Physics 1999 26 7 1371 1374 (Pubitemid 29334806)
70. Chen W. R., Carubelli R., Liu H., Nordquist R. E., Laser immunotherapy: a novel treatment modality for metastatic tumors. Applied Biochemistry and Biotechnology B 2003 25 1 37 43 2-s2.0-0041912552 10.1385/MB:25:1:37 (Pubitemid 37100236)
71. Chen W. R., Liu H., Ritchey J. W., Effect of different components of laser immunotherapy in treatment of metastatic tumors in rats. Cancer Research 2002 62 15 4295 4299 (Pubitemid 34827285)
72. Li X., Ferrel G. L., Guerra M. C., Preliminary safety and efficacy results of laser immunotherapy for the treatment of metastatic breast cancer patients. Photochemical & Photobiological Sciences 2011 10 5 817 821
73. Chen W. R., Korbelik M., Bartels K. E., Liu H., Sun J., Nordquist R. E., Enhancement of laser cancer treatment by a chitosan-derived immunoadjuvant. Photochemistry and Photobiology 2005 81 1 190 195 2-s2.0-14744281142 10.1562/2004-07-20-RA-236.1 (Pubitemid 40327579)
74. Le K., Li X., Figueroa D., Assessment of thermal effects of interstitial laser phototherapy on mammary tumors using proton resonance frequency method. Journal of Biomedical Optics 2011 16 12 128001
75. Yoon T. J., Kim J. Y., Kim H., Anti-tumor immunostimulatory effect of heat-killed tumor cells. Experimental and Molecular Medicine 2008 40 1 130 144 (Pubitemid 351346825)
76. Jager E., Jager D., Knuth A., Antigen-specific immunotherapy and cancer vaccines. International Journal of Cancer 2003 106 6 817 820 (Pubitemid 37071658)
77. Wu F., Zhou L., Chen W. R., Host antitumour immune responses to HIFU ablation. International Journal of Hyperthermia 2007 23 2 165 171 (Pubitemid 46404253)
78. Li X., Chen W. R., Laser immunotherapy: novel modality to treat cancer through specific antitumor immune response. Zhongguo Jiguang/Chinese Journal of Lasers 2010 37 11 2698 2702 2-s2.0-78650029113 10.3788/CJL20103711.2698
79. Segal B. H., Wang X. Y., Dennis C. G., Heat shock proteins as vaccine adjuvants in infections and cancer. Discovery Today 2006 11 11-12 534 540 (Pubitemid 43732542)
80. Liu B., Ye D., Song X., Zhao X., Yi L., Song J., Zhang Z., Zhao Q., A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis. Vaccine 2008 26 10 1387 1396 2-s2.0-39249084560 10.1016/j.vaccine.2007.12.034
81. Bolhassani A., Rafati S., Heat-shock proteins as powerful weapons in vaccine development. Expert Review of Vaccines 2008 7 8 1185 1199 2-s2.0-53849129597 10.1586/14760584.7.8.1185
82. Torigoe T., Tamura Y., Sato N., Heat shock proteins and immunity: application of hyperthermia for immunomodulation. International Journal of Hyperthermia 2009 25 8 610 616 2-s2.0-73649130637 10.3109/02656730903315831
83. Nishikawa M., Takemoto S., Takakura Y., Heat shock protein derivatives for delivery of antigens to antigen presenting cells. International Journal of Pharmaceutics 2008 354 1-2 23 27 2-s2.0-40849136114 10.1016/j.ijpharm.2007.09. 030 (Pubitemid 351400328)
84. Li X., Zhou F., Le H., Mechanism study of tumor-specific immune responses induced by laser immunotherapy. 7900 Biophotonics and Immune Responses VI 2011 Proceedings of SPIE 10.1117/12.873919
85. Geijtenbeek T. B. H., Gringhuis S. I., Signalling through C-type lectin receptors: shaping immune responses. Nature Reviews Immunology 2009 9 7 465 479 2-s2.0-67649840704 10.1038/nri2569
86. Zhou F., Song S., Chen W. R., Immunostimulatory properties of glycated chitosan. Journal of X-Ray Science and Technology 2011 19 2 285 292
87. Chen W. R., Jeong S. W., Lucroy M. D., Induced anti-tumor immunity against DMBA-4 metastatic mammary tumors in rats using a novel approach. International Journal of Cancer 2003 107 6 1053 1057 (Pubitemid 37429850)
88. Chen W. R., Singhal A. K., Liu H., Antitumor immunity induced by laser immunotherapy and its adoptive transfer. Cancer Research 2001 61 2 459 461 (Pubitemid 32128597)
89. Li X., Le H., Wolf R. F., Long-term effect on EMT6 tumors in mice induced by combination of laser immunotherapy and surgery. Integrative Cancer Therapies 2011 10 4 368 373
90. Peniche H., Peniche C., Chitosan nanoparticles: a contribution to nanomedicine. Polymer International 2011 60 6 883 889 2-s2.0-79956099797 10.1002/pi.3056
91. Sharma S., Mukkur T. K., Benson H. A., Enhanced immune response against pertussis toxoid by IgA-loaded chitosan-dextran sulfate nanoparticles. Journal of Pharmaceutical Sciences 2012 101 1 233 244
92. Wang J. J., Zeng Z. W., Xiao R. Z., Recent advances of chitosan nanoparticles as drug carriers. International Journal of Nanomedicine 2011 6 765 774
93. Yousefpour P., Atyabi E F., Vasheghani-Farahani E., Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab. International Journal of Nanomedicine 2011 6 1977 1990
94. Wen Z. S., Xu Y. L., Zou X. T., Xu Z. R., Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Marine Drugs 2011 9 6 1038 1055 2-s2.0-79959709054 10.3390/md9061038
95. Wu K. Y., Wu M., Fu M. L., Li H., Yang Y., Zhang H., Cheng C., Wang Z. Z., Wang X. Y., Lü X. B., Liu D. G., Li H., Gao R., A novel chitosan CpG nanoparticle regulates cellular and humoral immunity of mice. Biomedical and Environmental Sciences 2006 19 2 87 95 2-s2.0-33745192606 (Pubitemid 43904321)
96. Danesh-Bahreini M. A., Shokri J., Samiei A., Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice. International Journal of Nanomedicine 2011 6 835 842
97. Saranya N., Moorthi A., Saravanan S., Devi M. P., Selvamurugan N., Chitosan and its derivatives for gene delivery. International Journal of Biological Macromolecules 2011 48 2 234 238 2-s2.0-79551690025 10.1016/j.ijbiomac.2010.11.013
98. Park S., Jeong E. J., Lee J., Preparation and characterization of nonaarginine-modified chitosan nanoparticles for siRNA delivery. Carbohydrate Polymers 2013 92 57 62